Corden Pharma acquires Hospira Boulder manufacturing plant

BOULDER — Germany-based pharmaceutical manufacturer Corden Pharma International GmbH has agreed to acquire the Hospira Boulder manufacturing plant from New York-based Pfizer Inc.

Financial terms of the deal were not disclosed, but the deal is expected to close in November. Pfizer announced in June last year that it intended to close or sell the Hospira facility.

Hospira Boulder, to be renamed Corden Pharma Boulder, will be managed by Brian McCudden, chief executive of Corden Pharma Colorado Inc., who was responsible for Hospira Boulder during one of his previous assignments as an employee of Hospira.